Market capitalization | $26.54m |
Enterprise Value | $40.62m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.76 |
P/S ratio (TTM) P/S ratio | 1.15 |
P/B ratio (TTM) P/B ratio | 0.37 |
Revenue growth (TTM) Revenue growth | -2.09% |
Revenue (TTM) Revenue | $23.05m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a DarioHealth Corp. forecast:
3 Analysts have issued a DarioHealth Corp. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 23 23 |
2%
2%
|
|
Gross Profit | 9.20 9.20 |
7%
7%
|
|
EBITDA | -53 -53 |
16%
16%
|
EBIT (Operating Income) EBIT | -59 -59 |
18%
18%
|
Net Profit | -32 -32 |
43%
43%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. Its solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in Caesarea, Israel.
Head office | United States |
CEO | Erez Raphael |
Employees | 276 |
Founded | 2011 |
Website | www.dariohealth.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.